Liliia Hala

Liliia Hala

Auto-generated profile, based on publicly available information

Liliia Hala

Bogomolets National Medical University, Kyiv, Ukraine

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
27 October 2023 in Farmatsevtychnyi zhurnal
Verified
Journal Article
Open access
PDF file
ІНІ. В. Ніженковська
І. В. Ніженковська
МБМ. М. Бабенко
М. М. Бабенко
ЛГЛ. О. Гала
Л. О. Гала
NSNatalia Sholoiko
Natalia Sholoiko
НДН. О. Дацюк
Н. О. Дацюк
INI. V. Nizhenkovska
I. V. Nizhenkovska
The price of medicines is an important factor in ensuring accessibility for the population in the healthcare. Ukraine actively implements pricing policies in the healthcare in accordance with the recommendations of the World Health Organization (WHO). WHO recommendations aim to achieve two important objectives. First, they seek to ensure the availability of effective medicines for the population so that every patient has the opportunity to receive necessary treatment. Second, it is to create conditions for pharmaceutical companies to have incentives to continue their innovative activities in the field of medicine. The purpose of the research is to analyze and evaluate pricing policies that ensure the accessibility of medicines for the Ukrainian population through state budget funding and their compliance with WHO recommendations. It has been established that in Ukraine, there are several directions aimed at ensuring the population's accessibility to medicines through state budget funding: the purchase of medicines within the National Essential Medicine List, the «Affordable Medicines» program, centralized procurement of medicines and the purchase of innovative medicines through Managed Entry Agreements. Pricing for medicines under various programs is carried out using different approaches. An analysis of the legislative environment regulating medicine pricing in Ukraine in accordance with WHO-recommended pricing policies has revealed that several pricing policies are functioning at a satisfactory level. These include external and internal reference pricing, mark-up regulation, cost-based pricing, as well as tax exemptions or reductions for medicines. However, there are policies that require further development and improvement. These include promoting price transparency, conducting tenders and negotiations, consolidating procurement, promoting the use of generics and biosimilars with guaranteed quality, as well as introducing cost-plus pricing to determine medicine prices. Thus, standardization of the lists of medicines and pricing approaches is one of the most important tasks on the path to European integration. Monitoring market prices with control over their compliance is a necessary step to improve the population's access to effective medicines.

29 August 2022 in Farmatsevtychnyi zhurnal
Verified
Journal Article
Open access
PDF file
ЛГЛ. О. Гала
Л. О. Гала
ACA. O. Chubai
A. O. Chubai
In recent decades, every citizen tries for an active position regarding his own health. Such factors as improving the general level of medical literacy and quality of life of the population, developing of pharmaceutical market contribute to the spread of self-medication. The formation of the concept of responsible self-medication, which includes the free use by consumers of effective and safe over-the-counter (OTC) medicines has been the solution to the specified needs of society. The purpose of the study was to develop modern organizational approaches to the formation of the List of OTC medicines in Ukraine to ensure the proper level of pharmaceutical care. The objects of the study were the Lists of OTC medicines approved by orders of the Ministry of Health of Ukraine during 2010–2019; the register of medicines allowed to be dispensed without a prescription (according to the State Register of Medicines of Ukraine, as of February 2022); protocols of the pharmacist. The methods of marketing analysis, analytical-comparative, systematic, graphic and method of generalization were used. Based on the analysis of the Lists of OTC medicines valid in Ukraine in the relevant years (2010–2022), it was established that the number of OTC medicines and the specific weight of it in the registered drugs on the pharmaceutical market decrease annually (from 26.0% to 21.2%). According to the results of the comparative marketing analysis of the current List of OTC medicines (order of the Ministry of Health of Ukraine dated April 18, 2019 N 876) and the register of OTC medicines (according to the State Register of Drugs of Ukraine, as of February 2022), only insignificant differences were found in the distribution of assortment items by composition, ATC classification, countries of origin, dosage forms. Deficiencies of the current List of OTC medicines were identified, such as the presence of medicines with expired registration in 2019–2022; duplication of positions; the presence of trade names of the prescription group. According to the results of the research, organizational approaches that will contribute to the proper formation of the next edition of the domestic List of OTC medicines and its rational use by pharmacists and consumers to realize the possibilities of responsible self-medication are proposed. The results of the research can be used in the formation of a legal framework in Ukraine, which regulates the circulation of OTC medicines on the pharmaceutical market.

31 August 2022 in ScienceRise: Pharmaceutical Science
Verified
Journal Article
Open access
PDF file
MFMaryna Fedotova
Maryna Fedotova
HPHanna Panfilova
Hanna Panfilova
LHLiliia Hala
Liliia Hala
ALAlla Lebedyn
Alla Lebedyn
LSLiusine Simonian
Liusine Simonian
MVMariia Velia
Mariia Velia
The aim: to assess the state of pharmaceutical provision of patients with dementia in Alzheimer's disease in Ukraine in accordance with international recommendations. Materials and methods. In our studies, we used data from international guidelines, clinical protocols that regulate the organization of medical and pharmaceutical care for these patients in the USA, Australia, Japan, Germany, Great Britain, Finland, India, Kazakhstan, and Ukraine. The actual state of pharmaceutical provision of these patients in Ukraine was studied using a depersonalized database of medical prescriptions, which operates based on a number of specialized healthcare institutions. In addition, data from the Morion information search system were used. We used general theoretical (historical, formal, graphic, hypothetical-deductive, etc.) and applied (clinical-economic, organizational-economic, mathematical-statistical, etc.) research methods. Results. It has been established that a consolidated opinion has been formed in the world scientific community regarding the possibility of effective use in the pathogenetic treatment of patients with dementia in Alzheimer's disease of drugs from the groups N06DA Acetylcholinesterase inhibitors and N06DX-Other drugs for use in case of dementia. Thus, the pharmaceutical component of international recommendations, clinical protocols for the treatment of patients with dementia in Alzheimer's disease contains four drugs used in pathogenetic therapy. These are N06DA02 Donepezil, N06DA03 Rivastigmine, N06DA04 Galantamine and N06DX01 Memantine. It has been reported that all the above drugs are included in the domestic clinical protocol for the treatment of patients with dementia in Alzheimer's disease, the State Drug Formulary (with the exception of N06DA03 Rivastigmine), and the State Drug Registry. At the same time, all of them were absent from the National List of Essential Drugs, which has an important socio-economic and medical-pharmaceutical significance in the health care system. It was found that patients (200 people) received 2487 prescriptions (100.0 %), among which 9.41 % (234 prescriptions) were drugs used in pathogenetic treatment. There is a highly disproportionate nature of the distribution of prescriptions and consumption by international generic names of drugs. Thus, drugs N06DX01 Memantine accounted for 80.41 % (188 prescriptions) of all prescriptions in the group N06D Drugs for use in dementia, and the consumption rate was UAH 84420.20, which accounted for 91.48 % of the amount of expenses directed to patients with carrying out pathogenetic treatment. Significant dominance of drugs N06DX01 Memantine in the structure of prescriptions and consumption indicates the presence of severe, advanced forms of dementia in patients. This fact once again emphasizes the need for early detection and treatment of cognitive impairment, primarily for the rational use of limited health care resources. We have found that there are no prescriptions for N06D A04 Galantamine preparations, which are recommended by the relevant international recommendations in different countries of the world, as well as by the domestic clinical protocol for the pathogenetic treatment of mild and moderate forms of Alzheimer's disease. At the same time, N06DA05 Ipidacrine preparations were used in the treatment of domestic patients, which are not presented in the pharmaceutical component of international recommendations and protocols governing the pathogenetic treatment of the above-mentioned groups of neuropsychiatric patients. Conclusions. The peculiarities of the formation of the pharmaceutical component in the organization of the treatment process of patients with dementia in Alzheimer's disease in Ukraine, established by us, allow further research on the development of rational ways of resource provision of neuropsychiatric patients

27 November 2024 in News of Pharmacy
Verified
Journal Article
Open access
PDF file
LHL. O. Hala
L. O. Hala
KKK. L. Kosyachenko
K. L. Kosyachenko
ZPZh. M. Polova
Zh. M. Polova
LKL. V. Konoshevych
L. V. Konoshevych
Aim. To analyze the changes in the professional functions of pharmacists because of the growing social burden on pharmacies, as well as the prospects for this profession. Materials and methods. The objects of the study were regulatory legal acts on the regulation of pharmaceutical activities; modern approaches to the organization of pharmaceutical care and services to the population in Ukraine. To achieve this goal, the following methods were used: bibliographic, historical, content analysis, analytical-comparative, systematization and generalization. Results and discussion. Analyzed the legal acts of the period of Ukraine's independence aimed at forming a patient-oriented model of pharmacy functioning, in particular, the introduction of international quality standards, intensification of state policy to ensure the availability of medicines for the population, and elaboration of the requirements of good pharmacy practice at the present stage. It is proposed that the classical functions of pharmacy institutions (trade, production, information and social), due to the increasing content of the professional roles of pharmacists with the social component of their activities, should be outlined by complex conceptual categories formed from two fundamental activities – socio-economic, trade and production, information and communication, and social and humanitarian. The article considers the prospects for a pharmacist who, at the level of secondary specialization, can acquire new competencies in accordance with the professional standard and further apply for the position of a healthcare professional. As an example, the author characterizes the pharmacist's participation in the pharmacovigilance system – notifying the patient about the possibility of adverse reactions and the algorithm of actions in such a situation, collecting information on adverse drug reactions and health risks, filling out a card-notification of adverse reaction and/or lack of effectiveness of therapy. Conclusions. The expansion of the content of the professional functions of pharmacists and the growth of their role in society due to the increase in social burden contributes to the formation of a patient-oriented model of pharmacy functioning, but requires the implementation of the requirements of good pharmacy practice and the revision of related regulations to ensure the conditions for the quality provision of pharmaceutical care and services.

20 September 2019 in EUREKA: Health Sciences
Verified
Journal Article
Open access
PDF file
LHLiliia Hala
Liliia Hala
HPHanna Panfilova
Hanna Panfilova
The effectiveness of the system of pharmaceutical supply to the population depends on the proper interaction of the state and market mechanisms for regulating the interests of all subjects of the pharmaceutical market for the implementation of the social policy of the state regarding the availability of quality and effective medicines for the population. In the context of healthcare reform, the issues of assessing the main stages of the development of the pharmaceutical supply system of the population become especially relevant. Aim. Determination of key, from organizational, economic and social points of view, stages of formation of the domestic system of pharmaceutical supply of the population, analysis of the main tendencies of its development in retrospect years. Materials and methods. The materials of the research were selected by the regulatory acts, the data of the specialized literature, certain aspects of activity of subjects of the pharmaceutical market, etc. Methods such as historical, informational-analytical, analytical-comparative, systemic, logical, hypothetical-deductive and generalization were used. Results. Based on the conducted research, five stages of the formation of the pharmaceutical supply system have been identified and outlined, which differ fundamentally across the range of criteria for analyzing effectiveness in building relationships between the state, civil society and the professional community. These stages were elaborated in accordance with the results of the analysis of the nature of relations between the authorities and society under the conditions of gradual transition from paternalistic to the elements of the patient-oriented model of medical and pharmaceutical services to the population: 1) 1990–1993; 2) 1994–2000; 3) 2001–2007; 4) 2008–2013; 5) from 2014 to the present. It has been proved that the stages of development of the domestic pharmaceutical supply system depend to a large extent on the nature of the influence of external environmental factors: changes of political elites in the country, global and internal financial crises, changes of priorities of the state development, breaking of social consciousness of the population against the background of political crisis, etc. It should be noted that the most important in terms of positive, first of all socio-economic, development characteristics is the fourth stage of formation (2008-2013) of the domestic system of pharmaceutical supply of the population. The last period (since 2014) is characterized by the existence of a crisis of relations between all subjects in the system of pharmaceutical provision of the population against the background of systemic transformations in the state, strengthening of the role of public professional associations and critical raising of public expectations from the state regarding the organization of providing affordable medical care to the population. and pharmaceutical assistance in the face of mass impoverishment. Conclusion. The basic stages of the formation of the domestic pharmaceutical supply system are defined and their characteristics are envisaged, which allow to form in the future fundamentally new approaches to building rational, economically speaking, and simultaneously socially responsible relations between different subjects in the pharmaceutical market.

28 April 2025 in Farmatsevtychnyi zhurnal
Verified
Journal Article
Open access
PDF file
ІЖІ. В. Жогов
І. В. Жогов
ЛГЛ. О. Гала
Л. О. Гала
The concept of pharmaceutical care transforms the role of pharmacists in the healthcare system, expanding their functions from dispensing medications to counseling and managing pharmacotherapy, especially for chronic diseases. Research shows that integrating pharmacists into multidisciplinary teams improves treatment outcomes for chronic diseases. However, in Ukraine, the practical activities of pharmacists often do not meet the requirements for full implementation of the pharmaceutical care concept. It is necessary to implement not only basic but also specialized pharmaceutical services focused on prevention and medication therapy management. The aim of the work is to analyze the regulatory framework for the provision of pharmaceutical care and pharmaceutical services and approaches to their standardization for further optimization of such services in Ukraine. The research materials included regulatory acts of Ukraine and the EU, documents of pharmaceutical associations, and scientific publications. A systematic approach, content analysis, comparative analysis, and structural-logical method were applied. Definitions of pharmaceutical care and services in various documents were analyzed. The analysis showed that the key EU document is Resolution CM/Res(2020)3, which contains recommendations for implementing pharmaceutical care. In Ukraine, the concepts of pharmaceutical care and services were introduced into the legal field by the new edition of the Law «On Medicines». The main components of care provision were identified: professional interaction, assessment and planning, implementation and optimization, monitoring and evaluation, prevention and education, quality assurance. A hierarchical structure of types of regulatory acts governing standardization was developed. It was established that Ukrainian legislation, having introduced the concepts of pharmaceutical care and services for the first time, corresponds in content to European definitions. The research results emphasize the importance of a comprehensive approach to standardizing pharmaceutical care and services, which considers international experience and national features of the healthcare system. For effective implementation of the pharmaceutical care concept, it is necessary to develop regulatory acts at all levels, including national guidelines, standards, protocols, and standard operating procedures. Particular attention should be paid to developing documents on medication therapy management as a key element of pharmaceutical care, ensuring an individualized approach to treating patients with chronic diseases. Implementation of the proposed hierarchical structure of regulatory documents will allow systematizing the process of providing pharmaceutical care and services, improving their quality and effectiveness. This, in turn, will contribute to optimizing pharmacotherapy, reducing risks associated with medication use, and improving overall public health.